Pancreatic cancer is one of the deadliest
cancer and has surpassed breast cancer, moving from the fourth leading cause of
cancer-related death in the U.S. to the third position. According to the Pancreatic Cancer Action Network, in 2016, it was estimated that in the coming
years, 53,070 Americans will be diagnosed with pancreatic cancer, and 41,780
will die from the disease. While the overall cancer-related deaths are
decreasing, mortality rates associated with pancreatic cancer are constantly
increasing. Prime causes for pancreatic cancer include smoking, alcohol
consumption, and age above 60 to 80 years.
Global
pancreatic cancer treatment market, by region, 2015
Based
on the affected region, the pancreatic cancer treatment market is categorized
into endocrine and exocrine. The market for exocrine pancreatic cancer occupied
the largest market share in 2015 as it is the most common type of pancreatic
cancer and more than 95% of pancreatic cancers are classified as exocrine
tumors. The market for exocrine pancreatic cancer is expected to foresee the
fastest growth rate during the forecast period.
To request a sample copy or view summary of this report,
click the link below:
http://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market
http://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market
Chemotherapy and targeted therapy are the
treatment modalities that are used in pancreatic cancer. Growing use of
targeted therapy due to its effectiveness is expected to play an important role
in positively impacting the market growth.
Only
9% of the cases are diagnosed when the disease is in a confined stage. As on
date, no proven biomarkers are detected in the blood or other bodily fluids,
which could indicate the presence of pancreatic tumor at an early stage. There
are only four drugs that have been approved for the treatment of pancreatic
cancer by the U.S. FDA namely, Gemzar (Eli Lilly and Company) in 1996, Tarceva
(Genentech) in 2005, albumin-bound Abraxane (Celgene) in 2013, and Onivyde
(Merrimack) in 2015. The effectiveness of the presently available treatment
using the help of these drugs is still slow and majority of the patients still
rapidly succumb to the disease.
The
pancreatic cancer treatment market is fragmented with a number of companies
operating in the market. Players are investing heavily in research and
development to expand their product offerings to maintain a competitive
advantage over others. Some of the major players operating in this space
include, but are not limited to, Eli Lilly and Company; Celgene Corporation; F.
Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.;
Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.;
and Pfizer, Inc.
Access Press Release of Pancreatic Cancer Treatment Market@ https://www.grandviewresearch.com/press-release/global-pancreatic-cancer-treatment-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
